Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Antibiotic Legislation Should Focus On Criteria, Not Bacteria, Woodcock Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Congress should allow the agency to determine which drug-resistant bacteria sponsors should target in order to earn incentives for antibiotic development, rather than list specific pathogens, CDER Director Janet Woodcock suggested to a House panel March 8. The window to change the GAIN Act appears to be closing, though.

Advertisement

Related Content

Senate Prevails On PDUFA Antibiotic Incentive As House Vote Nears
PDUFA Negotiations: REMS Mud-Slinging, Supply Chain Compromising, GAIN Diminishing?
User Fee Conference Committee Targets Settling Differences In June
User Fee Conference Cmte. Could Be Relatively Messy After Clean Floor Votes
Antibiotic Policy Solutions An Ocean Apart Between U.S., EU
PDUFA Stars Aligning As House Draft Gives FDA Direct Authority Over Importers
Antibiotics Approval Changes GAINing Acceptance; PDUFA May Not Get LPADed Out
Orphan Antibiotics? Woodcock Says It May Be Possible If IDSA’s New Pathway Is Implemented
FDA Exploring Limited-Use Approvals For Antibiotics Based On Small Development Programs
Antibiotics Could Get Double Exclusivity Under House Bill; FDA Makes Its Own Moves

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073855

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel